A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours

The aim of this study is to define the maximum tolerated dose (MTD), safety, pharmacokinetics (PKs) and efficacy of ispinesib (SB-715992) in combination with docetaxel. Patients with advanced solid tumours were treated with ispinesib (6–12 mg m(−2)) and docetaxel (50–75 mg m(−2)). Docetaxel was admi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Blagden, S P, Molife, L R, Seebaran, A, Payne, M, Reid, A H M, Protheroe, A S, Vasist, L S, Williams, D D, Bowen, C, Kathman, S J, Hodge, J P, Dar, M M, de Bono, J S, Middleton, M R
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group 2008
Schlagworte:
Clinical Study
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2266864/
https://ncbi.nlm.nih.gov/pubmed/18319713
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604264
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge